REGENXBIO Files 2024 10-K
Ticker: RGNX · Form: 10-K · Filed: Mar 13, 2025 · CIK: 1590877
Sentiment: neutral
Topics: 10-K, biotechnology, financials
TL;DR
REGENXBIO dropped its 2024 10-K. Check financials & R&D.
AI Summary
REGENXBIO Inc. filed its 2024 10-K on March 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, a biotechnology firm specializing in biological products, is headquartered in Rockville, MD. The filing details its financial performance and business operations, including research and development expenses and general administrative costs.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of REGENXBIO's financial health and strategic direction for the fiscal year 2024, crucial for understanding the company's performance and future prospects.
Risk Assessment
Risk Level: medium — Biotechnology companies often face high risks due to the nature of drug development, regulatory hurdles, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-13 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- REGENXBIO Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-13 (date) — Filing date
- Rockville, MD (location) — Company headquarters
- BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] (industry) — Standard Industrial Classification
FAQ
What was REGENXBIO's primary business focus as of December 31, 2024?
As of December 31, 2024, REGENXBIO Inc. was primarily involved in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When was the 10-K filing for the fiscal year ending December 31, 2024, submitted?
The 10-K filing for the fiscal year ending December 31, 2024, was submitted on March 13, 2025.
Where is REGENXBIO Inc. headquartered?
REGENXBIO Inc. is headquartered at 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD 20850.
What is the SEC file number for REGENXBIO Inc.'s 10-K filing?
The SEC file number for REGENXBIO Inc.'s 10-K filing is 001-37553.
What are some of the key financial reporting categories mentioned in the filing's metadata?
The filing's metadata mentions categories such as Research and Development Expense, General and Administrative Expense, Retained Earnings, and Restricted Stock Units (RSUs).
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 13, 2025 regarding REGENXBIO Inc. (RGNX).